Catalyst Pharmaceuticals (NASDAQ:CPRX) highlighted continued growth in its rare disease portfolio and outlined efforts to expand patient identification and penetration for its lead product during a ...
Rapid Micro Biosystems, Inc. sees strong FY25 revenue growth from Growth Direct placements, but losses persist. Click for ...
Zacks Investment Research on MSN
CAH's pharma segment gains 19% in Q2'26: Is the growth sustainable?
Cardinal Health CAH once again delivered a robust performance in the fiscal second quarter of 2026, led by the continued strength of its core Pharmaceutical and Specialty Solutions segment. Segment ...
BioMarin Pharmaceutical (NASDAQ:BMRN) executives highlighted 2025 revenue growth, improving profitability leverage, and a slate of clinical and commercial catalysts expected in 2026 during a ...
Lupin plans its next phase of global growth in the US with a focus on complex generics, biosimilars and innovation, as the ...
Royalty Pharma plc (NASDAQ:RPRX) is among the 11 Best Low Priced Growth Stocks to Buy Right Now. On February 12, Goldman ...
Royalty Pharma (NASDAQ:RPRX) is one of the dirt cheap stocks to buy now. On February 11, Royalty Pharma reported a year of robust financial performance in 2025, marked by a 16% increase in total ...
Bank of America (BofA) Securities on Wednesday initiated coverage on Ligand Pharmaceuticals Inc LGND, citing the distinctive ...
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) will host an Investor Day in New York City today. Senior executives will provide an update on the company’s plans to ...
Aspen Pharmacare Holdings says its mixed performance reflects a transitional period, buoyed by strong commercial pharmaceuticals growth that offset a cancelled contract and costly factory ...
While Nifty Pharma giants struggle with regulatory headwinds and pricing pressures, two outliers are quietly catching the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results